Last reviewed · How we verify
Uroselective alpha-1-adrenergic receptor antagonist — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Uroselective alpha-1-adrenergic receptor antagonist (Uroselective alpha-1-adrenergic receptor antagonist) — Mayo Clinic.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Uroselective alpha-1-adrenergic receptor antagonist TARGET | Uroselective alpha-1-adrenergic receptor antagonist | Mayo Clinic | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Uroselective alpha-1-adrenergic receptor antagonist CI watch — RSS
- Uroselective alpha-1-adrenergic receptor antagonist CI watch — Atom
- Uroselective alpha-1-adrenergic receptor antagonist CI watch — JSON
- Uroselective alpha-1-adrenergic receptor antagonist alone — RSS
Cite this brief
Drug Landscape (2026). Uroselective alpha-1-adrenergic receptor antagonist — Competitive Intelligence Brief. https://druglandscape.com/ci/uroselective-alpha-1-adrenergic-receptor-antagonist. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab